OrthoACI

OrthoACI is an autologous chondrocyte implantation (ACI) cell therapy developed by Orthocell for the treatment of symptomatic articular cartilage defects in the knee and ankle. The therapeutic process involves harvesting a small biopsy of healthy cartilage from a non-weight-bearing area of the patient's joint. These cells are then isolated and expanded ex vivo in a specialized laboratory to produce a high-density population of chondrocytes. The expanded cells are subsequently re-implanted into the patient's cartilage defect, often under a collagen membrane, where they facilitate the regeneration of functional hyaline-like cartilage. This approach aims to restore joint function, reduce pain, and prevent the progression of osteoarthritis. OrthoACI is currently approved and commercially available in Australia.

Brand names

OrthoACI

Other names

autologous chondrocyte implantation